4,5-dihydro-1(2)H-benz[g]indazole-3-carboxylic acid | 856257-31-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4,5-dihydro-1(2)H-benz[g]indazole-3-carboxylic acid
• 英文别名: 4,5-Dihydro-1(2)H-benz[g]indazol-3-carbonsaeure；4,5-dihydro-[1H]-benz[g]indazole-3-carboxylic acid；4,5-dihydro-1H-benzo[g]indazole-3-carboxylic acid；4,5-dihydro-2H-benzo[g]indazole-3-carboxylic acid
• CAS: 856257-31-3；898796-47-9
• 化学式: C₁₂H₁₀N₂O₂
• mdl: MFCD03030185
• 分子量: 214.224
• InChiKey: VWDJLWDAXLFYCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4,5-dihydro-1(2)H-benz[g]indazole-3-carboxylic acid 在 盐酸 作用下， 生成 4,5-dihydro-benz[g]indazole-1,3-dicarboxylic acid diethyl ester
  参考文献：
  名称：

  v. Auwers; Enbergs, Journal fur praktische Chemie (Leipzig 1954), 1932, vol. <2> 134, p. 97,102, 103

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 4,5-dihydro-1H-benzo[g]indazole-3-carboxylate 在 氢氧化钾 作用下， 生成 4,5-dihydro-1(2)H-benz[g]indazole-3-carboxylic acid
  参考文献：
  名称：

  v. Auwers; Enbergs, Journal fur praktische Chemie (Leipzig 1954), 1932, vol. <2> 134, p. 97,102, 103

  摘要：

  DOI：

文献信息

• Substituted pyrazolyl compounds for the treatment of inflammation
  申请人：——

  公开号：US20030114432A1

  公开（公告）日：2003-06-19

  The present invention relates to substituted pyrazolyl derivatives, compositions comprising such, intermediates, methods of making substituted pyrazolyl derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.

  本发明涉及取代吡唑基衍生物，包含这种衍生物的组合物，中间体，制备取代吡唑基衍生物的方法，以及治疗癌症、炎症和与炎症相关的疾病，如关节炎的方法。
• [EN] BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION<br/>[FR] DERIVES DE BENZOPYRANOPYRAZOLYLE POUR LE TRAITEMENT DES INFLAMMATIONS
  申请人：G.D. SEARLE & CO.

  公开号：WO1996009304A1

  公开（公告）日：1996-03-28

  (EN) A class of benzopyranopyrazolyl derivatives is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by formula (I) wherein A is -(CH2)m-X-(CH2)n-; wherein X is S(O)p or O; wherein m is 0 or 1; wherein n is 0 or 1; wherein p is 0 or 1; wherein B is selected from phenyl and five and six membered heteroaryl; wherein R1 is selected from lower haloalkyl, cyano, lower hydroxyalkyl, formyl, lower alkoxycarbonyl, lower alkoxy, lower N-alkylaminocarbonyl, N-phenylaminocarbonyl, lower N,N-dialkylaminocarbonyl and lower N-alkyl-N-phenylaminocarbonyl; wherein R2 is phenyl substituted at a substitutable position with a radical selected from lower alkylsulfonyl and aminosulfonyl; and wherein R4 is one or more radicals selected from hydrido, halo, lower alkylthio, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, aminocarbonyl, lower haloalkyl, hydroxyl, lower alkoxy, amino, lower N-alkylamino, lower N,N-dialkylamino, lower hydroxyalkyl and lower haloalkoxy; or a pharmaceutically-acceptable salt thereof.(FR) L'invention concerne une classe de dérivés de benzopyranopyrazolyle destinés à être utilisés dans le traitement des inflammations et les troubles apparentés à une inflammation. Les composés présentant un intérêt particulier répondent à la formule (I) dans laquelle: A représente -(CH2)m -X-(CH2)n, où X représente S(Op) ou O, m vaut 0 ou 1, n vaut 0 ou 1, et p vaut 0 ou 1; B est choisi entre phényle et un groupe hétéroaryle à cinq ou six chaînons; R1 est choisi parmi haloalkyle inférieur, cyano, hydroxyalkyle inférieur, formyle, alcoxycarbonyle inférieur, alcoxy inférieur, N-alkylaminocarbonyl inférieur, N-phénylaminocarbonyle, N,N-dialkylaminocarbonyl inférieur et N-alkyl-N-phénylaminocarbonyl inférieur; R2 représente un phényle substitué dans une position de substitution par un radical choisi entre alkysulfonyle inférieur et aminosulfonyle; et R4 représente un ou plusieurs radicaux appartenant au groupe hybrido, halo, alkylthio inférieur, alkylsufinyle inférieur, alkyle inférieur, cyano, carboxyl, alcoxycarbonyl inférieur, aminocarbonyl, haloalkyle inférieur, hydroxyle, alcoxy inférieur, amino, N-alkylamino inférieur, N,N-dialkylamino inférieur, hydroxyalkyl inférieur et haloalcoxy inférieur. L'invention concerne également un sel pharmaceutiquement acceptable desdits dérivés.

  描述了一类苯并吡唑基衍生物，用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由式(I)定义，其中A为-(CH2)m-X-(CH2)n-；其中X为S(O)p或O；其中m为0或1；其中n为0或1；其中p为0或1；其中B选自苯基和五元和六元杂环基；其中R1选自低卤代烷基、氰基、低羟基烷基、甲酰基、低烷氧羰基、低烷氧基、低N-烷基氨基羰基、N-苯基氨基羰基、低N,N-二烷基氨基羰基和低N-烷基-N-苯基氨基羰基；其中R2为苯基，在可取代位置上用从低烷基磺酰基和氨基磺酰基中选择的基团取代；其中R4为一个或多个从氢、卤素、低烷基硫基、低烷基亚磺酰基、低烷基、氰基、羧基、低烷氧羰基、氨基羰基、低卤代烷基、羟基、低烷氧基、氨基、低N-烷基氨基、低N,N-二烷基氨基、低羟基烷基和低卤代烷氧基中选择的基团；或其药学上可接受的盐。
• Pyrrole and Pyrazole DAAO Inhibitors
  申请人：Fang Q. Kevin

  公开号：US20100016397A1

  公开（公告）日：2010-01-21

  Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.

  增加D-丝氨酸浓度并减少D-丝氨酸氧化产物浓度的方法，以增强学习、记忆和/或认知能力，或治疗精神分裂症、阿尔茨海默病、共济失调或神经病理性疼痛，或预防神经退行性疾病特征性神经元功能损失，包括向需要治疗的受试者施用公式I的化合物或其药学上可接受的盐或溶剂的治疗有效量：其中，R1和R2分别选自氢、卤素、硝基、烷基、酰基、烷基芳基和XYR5；或R1和R2共同形成5、6、7或8成员取代或未取代的碳环或杂环基；X和Y分别选自O、S、NH和（CR6R7）n；R3为氢、烷基或M+；M为铝离子、钙离子、锂离子、镁离子、钾离子、钠离子、锌离子或其混合物；Z为N或CR4；R4选自氢、卤素、硝基、烷基、烷基芳基和XYR5；R5选自芳基、取代芳基、杂芳基和取代杂芳基；R6和R7分别选自氢和烷基；n为1到6的整数；R1、R2和R4中至少有一个不是氢；X和Y中至少有一个是（CR6R7）n。D-丝氨酸或环丝氨酸可以与公式I的化合物一起共同施用。
• PYRROLE AND PYRAZOLE DAAO INHIBITORS
  申请人：FANG Q. Kevin

  公开号：US20110092559A1

  公开（公告）日：2011-04-21

  Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.

  增加D-丝氨酸浓度和减少D-丝氨酸氧化的有毒产物浓度的方法，以增强学习、记忆和/或认知能力，或用于治疗精神分裂症、阿尔茨海默病、共济失调或神经病理性疼痛，或预防神经退行性疾病特征性神经元功能丧失，包括向需要治疗的受试者施用公式I的化合物的治疗有效量，或其药学上可接受的盐或溶剂：其中，R1和R2分别选自氢、卤、硝基、烷基、酰基、烷基芳基和XYR5；或R1和R2一起形成一个5、6、7或8成员的取代或未取代的碳环或杂环基；X和Y分别选自O、S、NH和（CR6R7）n；R3是氢、烷基或M+；M是铝、钙、锂、镁、钾、钠、锌离子或其混合物；Z是N或CR4；R4选自氢、卤、硝基、烷基、烷基芳基和XYR5；R5选自芳基、取代芳基、杂芳基和取代杂芳基；R6和R7分别选自氢和烷基；n是1到6的整数；R1、R2和R4中至少有一个不是氢；X和Y中至少有一个是（CR6R7）n。D-丝氨酸或环丝氨酸可以与公式I的化合物一起共同施用。
• (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease
  申请人：Herbert Brian

  公开号：US20100298306A1

  公开（公告）日：2010-11-25

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds, which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. The novel compounds include compounds of formula I: wherein X, R 1 , and R 2 are as herein defined.

  本发明一般涉及尼古丁乙酰胆碱受体（nACh受体）配体领域，nACh受体的激活以及与缺陷或功能障碍的尼古丁乙酰胆碱受体相关的疾病状况的治疗，特别是大脑的疾病状况。此外，本发明涉及新型化合物，其作为α7 nACh受体亚型的配体，制备这种化合物的方法，含有这种化合物的组合物以及其使用方法。这些新型化合物包括I式化合物，其中X，R1和R2的定义如本文所述。